SHB-02-CD19 / Sheba Medical Center - LARVOL DELTA

A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies (clinicaltrials.gov) - P1/2 | N=50 | Not yet recruiting | Sponsor: Sheba Medical Center

New P1/2 trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • KMT2A • PBX1 • TCF3 • TP53